41100-45-2Relevant articles and documents
PROCESS FOR PRODUCING 3-ETHYL-1-ADAMANTYLAMINE
-
, (2020/10/16)
PROBLEM TO BE SOLVED: To provide an industrially economical and efficient synthetic method of 3-ethyl-1-adamantylamine, which does not include a synthetic process of 1-bromo-3-ethyladamantane which uses harmful halogen and which, in a synthetic reaction of 1-amide-3-ethyladamantane, suppresses by-products and improves a yield by reducing amounts of use of an amide or an acid and a nitrile relative to adamantanes, and also remarkably reduces wastes derived from the amide or the acid and the nitrile. SOLUTION: A method for producing 3-ethyl-1-adamantylamine comprises the following steps (i) to (iii): (i) a step of obtaining a reaction mixture by reacting 3-ethyl-1-adamantanol with an acid and a nitrile in an organic solvent; (ii) a step of obtaining 1-amide-3-ethyladamantane by adding water to the reaction mixture obtained in the step (i); and (iii) a step of hydrolyzing 1-amide-3-ethyladamantane obtained in the step (ii) in the presence of an alcohol-containing solvent and an inorganic base. COPYRIGHT: (C)2015,JPO&INPIT
METHODS OF TREATING CNS DISORDERS
-
, (2009/12/02)
The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
-
, (2008/06/13)
The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.